Male urinary tract infections (MUTI) are often less recognised compared to those in women. French clinical guidelines practices recommend the use of antibiotics called fluoroquinolones, which are highly effective in treating MUTIs. However, these antibiotics can lead to rare but serious side effects, such as tendonitis or heart rhythm disturbances. Additionally, fluoroquinolones can contribute to the development of bacterial resistance, making their use inadvisable within six months of treatment.
In response to these concerns, we aim to explore a well-established alternative, fosfomycin trometamol (known by the brand name MONURIL®). This antibiotic has a strong track record in treating UTIs in women, with well-documented benefits and minimal associated risks.
The primary goal of this study is to assess the effectiveness of fosfomycin trometamol in treating urinary tract infections in men, as well as to evaluate any potential treatment failures.

开始日期2025-06-01

申办/合作机构-

CTIS2024-513465-39-00

/ Recruiting临床4期IIT

Clinical Efficacy of oral Fosfomycin Trometamol and Cefixime in the Treatment of Acute Bacterial Prostatitis (CEFOSPROST): a comparative, randomized, open, multicenter trial. - CEFOSPROST

开始日期2024-12-17

申办/合作机构-

CTR20242961

/ CompletedN/A

江苏联环药业股份有限公司研制的磷霉素氨丁三醇颗粒（3 g）与Zambon Switzerland Ltd.生产的磷霉素氨丁三醇颗粒（3 g）在中国健康受试者中进行的随机、开放、单剂量、两序列、两周期、交叉、空腹状态下的生物等效性研究

以江苏联环药业股份有限公司研制的磷霉素氨丁三醇颗粒（规格：3 g）为受试制剂，以Zambon Switzerland Ltd.生产的磷霉素氨丁三醇颗粒（商品名：Monurol®，规格：3 g）为参比制剂，考察两制剂在空腹状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性；同时评价两种制剂在健康人体中的安全性和耐受性。

开始日期2024-08-21

申办/合作机构

江苏联环药业股份有限公司

100 项与磷霉素氨丁三醇相关的临床结果

登录后查看更多信息

100 项与磷霉素氨丁三醇相关的转化医学

登录后查看更多信息

100 项与磷霉素氨丁三醇相关的专利（医药）

登录后查看更多信息

350

项与磷霉素氨丁三醇相关的文献（医药）

2025-03-01·Prostate International

Single-dose vs prolonged antibiotic prophylaxis of fosfomycin for transrectal prostate biopsy: a single-center prospective, randomized, controlled trial

Article

作者: Lázár, Andrea ; Rárosi, Ferenc ; Burián, Katalin ; Fehér, Ádám Miklós ; Köves, Béla ; Czimbalmos, Nándor ; Bajory, Zoltán ; Fehér, Ádám M

BackgroundTransrectal prostate biopsy is a commonly performed urological procedure in which antibiotic prophylaxis is recommended. Fluoroquinolone-type antibiotics are no longer acceptable in the EU. Fosfomycin-trometamol may be used, but there is no evidence regarding its ideal dose and administration time.MethodsPatients who underwent prostate biopsy between 2021 and 2023 were evaluated prospectively. 204 patients were randomized into two arms: 102 patients (Arm A) received a single-dose of fosfomycin-trometamol one hour before surgery, and 102 patients (Arm B) received one additional dose of fosfomycin-trometamol 48 hours after the first dose. Urine tests and questionnaires were administered during the postoperative period and the subsequent four weeks to identify any symptoms, infectious, or other complications.ResultsThere was no statistical difference in the rate of asymptomatic bacteriuria (4.90% (5) vs. 8.82% (9), P = 0.27) symptomatic urinary tract infection (0% (0) vs. 1.96% (2), P = 0.50), or febrile urinary tract infection (0% (0) vs. 0.98% (1), P = 1) between the groups. Only hematuria was significantly more common in Arm B (6.86% (7) vs. 16.67% (17), P = 0.03), whereas other complications did not differ significantly. There was no statistical difference in hospitalization (0.98% (1) vs. 2.94 (3), P = 0.62) or mortality rate (0 % (0) vs. 0.98% (1), P = 1). Sub-group analysis of previous antibiotic users showed no difference in terms of complications.ConclusionThere is no significant difference in infectious complications between single-dose and prolonged prophylaxis of fosfomycin-trometamol for transrectal prostate biopsy. A single-dose of fosfomycin one hour before biopsy is an ideal choice with a better ecological impact compared with prolonged antibiotic prophylaxis for transrectal prostate biopsy.

2025-01-01·Environmental Research

A phenotypic study of the resistome in a peri-urban ecosystem

Article

作者: Román, Ana Carmen González ; Espigares Rodríguez, Elena ; González Román, Ana Carmen ; López Guarnido, Olga ; Dib, Amira Leila ; García Valdés, Luz María ; González Domenech, Carmen María

Since the discovery of antibiotics, the dispersion of resistance genes has increased exponentially, leading to the current state in which it has become increasingly difficult to achieve an effective treatment for infectious diseases. The enormous capacity for genetic exchange between microorganisms is causing resistance genes to be able to reach all environments, even those where there is no anthropogenic impact or exposure to these drugs. In this work, a phenotypic study of the resistome has been conducted in a peri-urban ecosystem (Granada, Spain), wherein the resistance to 32 antibiotics of 710 bacterial strains isolated from 70 samples from different ecological niches with varying levels of exposure to antibiotics and anthropic action has been determined. The study of resistances using phenotypic procedures constitutes a very useful and complementary alternative to genomic methods. The obtained results show a high percentage of resistance in all the subsystems analysed, stating high multi-resistance profiles. Vancomycin and erythromycin were the antibiotics to which the highest levels of resistance were observed, whereas the lowest levels were obtained in chloramphenicol. Regarding the environments studied, the highest percentages of resistance were found in wastewater, farms and food. It should be noted that in natural soil samples (not exposed to antibiotics or anthropogenic activities), worrying levels of resistance to practically all the groups of antibiotics analysed were detected. These results support the generally accepted conclusion that an appropriate control and management of wastewater and solid waste that may contain antibiotics or resistant bacteria is really important to prevent the wide propagation of the resistome in the environment.

2024-09-02·Urologiia

Новые перспективы консервативного лечения хронического рецидивирующего цистита у женщин: опыт применения лекарственного препарата Суперлимф®

Article

作者: Nasaeva, Nasaeva E.D. ; Nasaeva E, D ; Tevlin K, P ; Tevlina, Tevlina E.V. ; Sudilovskaya V, V ; Khanaliev, Khanaliev B.V. ; Khanaliev B, V ; Gankovskaya L, V ; Gankovskaya, Gankovskaya L.V. ; Tevlina E, V ; Sudilovskaya, Sudilovskaya V.V. ; Khasanova E, M ; Khasanova, Khasanova E.M. ; Tevlin, Tevlin K.P.

INTRODUCTIONChronic recurrent cystitis is a common and difficult problem of modern urology. Traditional use of antimicrobial drugs often cannot lead to the long-term remission.AIMTo evaluate the efficacy and safety of using different dosages and routes of the drug Superlymph in rectal and vaginal suppositories 10 U and 25 U in patients with chronic recurrent cystitis.MATERIALS AND METHODSA randomized comparative clinical study in parallel groups included 60 patients aged from 18 to 80 years with a diagnosis of chronic recurrent bacterial uncomplicated cystitis. All study participants were randomized into three groups. In Group 1 (n=25), Superlymph suppositories 25 U were prescribed rectally once a day for 20 days. In group 2 (n=25), Superlymph suppositories 10 U were administered vaginally 2 times a day, for 20 days. In accordance with the prescription information, Superlymph 10 U/25 U can be used vaginally or rectally depending on the gender. In addition, it is possible to change the route of administration, for example, Superlymph 25 U one suppository once a day or Superlymph 10 U, one suppository 2 times a day in the morning and in the evening. The duration of the course is from 10 to 20 days. The main aim of the study was to compare an influence of various route of administration of Superlymph in women with frequent relapses of cystitis on the urothelium according to biopsy results, as well as on the symptoms of recurrent cystitis. The reparative effect of Superlymph was evaluated as well. In the control group (n=10), standard therapy was administered (fosfomycin trometamol 3.0 g once, and then, on the next day from the start of therapy, nitrofurantoin 100 mg three times a day for 5 days). The study consisted of screening, therapy and follow-up stages. The duration of therapy was 20 days. All groups did not differ significantly in the main baseline characteristics.RESULTSThe drug Superlymph demonstrated efficacy as monotherapy of uncomplicated lower urinary tract infection in women compared with standard treatment. Rectal administration of the drug was more effective than vaginal. This was primarily manifested by a decrease in the level of urothelial metaplasia by the end of the study by 41% in the group of rectal suppositories and by 9% for the vaginal suppositories. In the control group, no changes in the level of metaplasia were found. A symptom scale showed an improvement of 36% in the group of rectal suppositories, 25% in the group of vaginal suppositories, and 19% in the control group. Improvements in the quality-of-life score were 50.8%, 33.9%, and 31.1%, respectively. The mean pelvic pain symptom scale score improved by 30%, 23%, and 13%, while a decrease in the mean leukocytes level in urine was most significant in the group of vaginal suppositories, by 39%. The respective indicators in the group of rectal suppositories and the control group were 27% and 21%, respectively. Innate immune factors were also assessed. The evaluation of gene expression levels in the bladder mucosa after using Superlymph was also performed. A significant decrease in TLR4 gene expression by 3 times, TNF gene expression by 4.2 times, and HBD1 expression by 2.7 times was found, which indicates a significant decrease in the level of inflammation in the bladder mucosa.CONCLUSIONThe immunomodulator Superlymph, representing a complex of natural antimicrobial peptides and cytokines, has demonstrated efficacy as monotherapy of chronic recurrent cystitis in women compared to standard treatment. Rectal route of administration was more effective than vaginal. This was primarily manifested by a decrease in the level of urothelial metaplasia by the end of the study. Therefore, the rectal suppositories should be used in older patients with a long history of the cystitis as intermittent therapy.

项与磷霉素氨丁三醇相关的新闻（医药）

2025-04-29

·药融圈

开元制药年产600吨磷霉素左磷右胺盐、250吨磷霉素钙、50吨磷霉素钠、50吨磷霉素氨丁三醇等项目验收

▲8月1-2日 2025生物医药创新博览会扫码报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。近日，关于开元制药（安徽）有限公司年产600吨磷霉素左磷右胺盐、250吨磷霉素钙、50吨磷霉素钠、50吨磷霉素氨丁三醇及1000kg蔗糖八硫酸酯盐等项目验收在相关网站公示。项目位于宿州经济开发区金江五路368号，项目占地面积约80.02亩，其中生产车间5894.97平方米、甲类仓库714平方米、甲类罐区969.77平方米、办公楼2417.76平方米。建设酯化氢化环氧车间、拆分精制回收车间、原料药车间并配套相关废气污染治理措施和污水处理站。项目建成后，形成年产600吨磷霉素左磷右胺盐、300吨磷霉素右磷左胺盐、250吨磷霉素钙、50吨磷霉素钠、50吨磷霉素氨丁三醇及1000kg蔗糖八硫酸酯盐的产能。项目于2023年12月投入调试，工程实际投资20245万元，其中环保投资2000万元，约占总投资的9.88%，主要环保设施包括：废气治理设施、废水处理装置、噪声治理措施、固废收集处置、环境风险防范措施等。版权声明：本文转自原料药情报局，如不希望被转载的媒体或个人可与我们联系，我们将立即删除会议推荐 | 点击查看详情植根上海、辐射全球,药融圈作为生物医药产业级战略平台,以"让智慧与人脉无界流动"为使命,构建覆盖药物研发、生产、流通、商业化的全产业链赋能体系。通过智能化云服务、精准资源链接、产业智库与生态社群四大核心引擎,打造中国医药价值流动的基础设施。在全球化与数字化双重浪潮下,药融圈正重新定义医药资源的流通范式--这里不仅是信息与人脉的枢纽站,更是催生产业变革的化学反应器。我们以中国为原点,编织全球医药智慧网络,让每一次精准链接都成为企业跨越式增长的催化剂。点点赞点分享点推荐

2025-04-18

·米内网

【市场】海南药企入局50亿口服降糖药

精彩内容日前，CDE官网显示，海南赛立克药业的达格列净片以仿制4类报产在审。米内网数据显示，达格列净片在2023年在中国三大终端六大市场（统计范围见文末）销售规模超过50亿元；2024年上半年同比增长近40%，是糖尿病用药（化+生）TOP1产品。截至目前，海南赛立克药业已有11款产品报产在审。达格列净片是口服钠-葡萄糖共转运蛋白2(SGLT2)抑制剂，通过抑制SGLT2，减少滤过葡萄糖的重吸收，降低葡萄糖的肾阈值，从而增加尿糖排泄，主要用于2型糖尿病成人患者、心力衰竭成人患者和慢性肾脏病成人患者的治疗。近年中国三大终端六大市场达格列净片销售情况（单位：万元）来源：米内网格局数据库达格列净片在2023年中国三大终端六大市场销售规模超过50亿元；2024年上半年同比增长近40%，是糖尿病用药（化+生）TOP1产品。米内网数据显示，达格列净片有25家企业拥有生产批文，福元药业、江苏德源药业、浙江华海药业等24家企业过评，海南赛立克药业、惠升生物制药、湖南千金湘江药业等28家报产在审。海南赛立克药业报产在审产品来源：米内网中国申报进度（MED）数据库截至目前，海南赛立克药业已有11款产品报产在审，涵盖呼吸系统用药、心脑血管系统药物、肌肉-骨骼系统等治疗大类。其中，达格列净片、沙库巴曲缬沙坦钠片、氟比洛芬凝胶贴膏、洛索洛芬钠凝胶贴膏和依帕司他片在2023年中国三大终端六大市场均是超10亿元重磅品种，磷霉素氨丁三醇颗粒、精氨酸布洛芬片、乙酰半胱氨酸片冲刺首仿。资料来源：CDE官网、米内网数据库等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

专利侵权

2025-04-07

·信狐药迅

北京永泰首款实体瘤细胞治疗爱可仑赛注射液提交上市申请|新受理（3.31-4.6）

本周药品注册受理数据，分门别类呈现，一目了然。(3.31-4.6）新药上市申请药品名称企业注册分类受理号爱可仑赛注射液北京永泰生物制品有限公司1CXSS2500039新药临床申请药品名称企业注册分类受理号VCT220片苏州闻泰医药科技有限公司1CXHL2500355VCT220片苏州闻泰医药科技有限公司1CXHL2500354VCT220片苏州闻泰医药科技有限公司1CXHL2500353JMKX005425片上海济煜医药科技有限公司1CXHL2500352SHR2554片江苏恒瑞医药股份有限公司1CXHL2500347SNH-119014片赛诺哈勃药业(成都)有限公司1CXHL2500346SNH-119014片赛诺哈勃药业(成都)有限公司1CXHL2500345SNH-119014片赛诺哈勃药业(成都)有限公司1CXHL2500344枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500351枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500350枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500349枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500348自复制RNA带状疱疹疫苗嘉晨西海(杭州)生物技术有限公司1.2CXSL2500259Cizutamig注射液上海坦蒂生物医药科技有限公司1CXSL2500265ZHB118舌下片江苏众红生物工程创药研究院有限公司1CXSL2500264LM-168注射液礼新医药科技(上海)有限公司1CXSL2500260ZHB118舌下片江苏众红生物工程创药研究院有限公司1CXSL2500263MRG007乐普生物科技股份有限公司1CXSL2500262IMC-003宜明凯尔生物医药技术(上海)有限公司1CXSL2500261注射用SHR-A1904苏州盛迪亚生物医药有限公司1CXSL2500258注射用SHR-A2102苏州盛迪亚生物医药有限公司1CXSL2500256重组抗CD19m-CD3抗体注射液天劢源和生物医药(上海)有限公司1CXSL2500255注射用SHR-A1811苏州盛迪亚生物医药有限公司1CXSL2500254SHR-1701注射液苏州盛迪亚生物医药有限公司1CXSL2500253阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500257仿制药申请药品名称企业注册分类受理号二羟丙茶碱注射液山东益健药业有限公司3CYHS2501299乙酰半胱氨酸片海南赛立克药业有限公司3CYHS2501292氯化钙注射液武汉市小铂生物科技有限公司3CYHS2501282吲哚布芬片郑州韩都药业集团有限公司3CYHS2501281维生素B6注射液扬州中宝药业股份有限公司3CYHS2501245右酮洛芬氨丁三醇片四川科瑞德制药股份有限公司3CYHS2501242右酮洛芬氨丁三醇片四川科瑞德制药股份有限公司3CYHS2501241托伐普坦口腔崩解片浙江和泽医药科技股份有限公司3CYHS2501277乙酰半胱氨酸注射液广东君康药业有限公司3CYHS2501276富马酸酮替芬口服溶液江苏润恒制药有限公司3CYHS2501275维生素B6注射液江苏悦兴医药技术有限公司3CYHS2501255盐酸溴己新口服溶液湖北海美纳医药科技有限公司3CYHS2501253复合磷酸氢钾注射液安徽双鹤药业有限责任公司3CYHS2501270依巴斯汀口服溶液江西心正药业有限责任公司3CYHS2501258硫代硫酸钠注射液江苏九旭药业有限公司3CYHS2501257泛昔洛韦片浙江车头制药股份有限公司3CYHS2501240泛昔洛韦片浙江车头制药股份有限公司3CYHS2501239注射用硫酸多黏菌素B福安药业集团烟台只楚药业有限公司3CYHS2501237氟哌啶醇口服溶液上海理想制药有限公司3CYHS2501233盐酸戊乙奎醚注射液国药集团工业有限公司廊坊分公司4CYHS2501254阿那曲唑片海南日中天制药有限公司4CYHS2501251布瑞哌唑片昆山龙灯瑞迪制药有限公司4CYHS2501248玻璃酸钠滴眼液四川禾亿制药有限公司4CYHS2501298玻璃酸钠滴眼液四川禾亿制药有限公司4CYHS2501297钆特酸葡胺注射液广州康臣药业有限公司4CYHS2501296甘油磷酸钠注射液山东华鲁制药有限公司4CYHS2501295甘油磷酸钠注射液山东华鲁制药有限公司4CYHS2501294复方托吡卡胺滴眼液浙江尖峰药业有限公司4CYHS2501293复方托吡卡胺滴眼液浙江尖峰药业有限公司4CYHS2501291碳酸镧咀嚼片浙江仟源海力生制药有限公司4CYHS2501290长链脂肪乳注射液(OO)江苏盈科生物制药有限公司4CYHS2501289低钙腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501288低钙腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501287低钙腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501286低钙腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501285低钙腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501284低钙腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501283夫西地酸乳膏杭州民生药业股份有限公司4CYHS2501246来特莫韦注射液苏州第壹制药有限公司4CYHS2501244妥布霉素滴眼液润尔眼科药物(广州)有限公司4CYHS2501243枸橼酸钠血滤置换液山东齐都药业有限公司4CYHS2501280盐酸伐地那非片江西施美药业股份有限公司4CYHS2501279盐酸伐地那非片江西施美药业股份有限公司4CYHS2501278艾拉莫德片山东现代医药科技有限公司4CYHS2501274米库氯铵注射液中玉制药(海口)有限公司4CYHS2501273复方氨基酸注射液(18AA-VII)湖北长联杜勒制药有限公司4CYHS2501272双氯芬酸钠缓释片江苏万高药业股份有限公司4CYHS2501252乳果糖口服溶液大玮(安徽)药业有限公司4CYHS2501271西甲硅油乳剂南通广承制药有限公司4CYHS2501250腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501269蛋白琥珀酸铁口服溶液海南康成药业有限公司4CYHS2501249腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501268夫西地酸乳膏杭州民生药业股份有限公司4CYHS2501247腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501267腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501266腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501265腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501264他达拉非片国大(吉林)制药集团有限公司4CYHS2501263他达拉非片国大(吉林)制药集团有限公司4CYHS2501262他达拉非片国大(吉林)制药集团有限公司4CYHS2501261注射用头孢他啶阿维巴坦钠山东致泰医药技术有限公司4CYHS2501260枸橼酸托法替布缓释片南京易亨制药有限公司4CYHS2501259非奈利酮片杨凌科森生物制药有限责任公司4CYHS2501256阿达帕林凝胶珠海市汇通达医药有限公司4CYHS2501238盐酸罗哌卡因注射液河南普瑞药业有限公司4CYHS2501236盐酸罗哌卡因注射液河南普瑞药业有限公司4CYHS2501235亚甲蓝肠溶缓释片南京正大天晴制药有限公司4CYHS2501234司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500043司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500042司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500041司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500040西帕依固龈液宁波卓仑医药科技有限公司4CYZS2500005进口申请药品名称企业注册分类受理号Clesrovimab注射液Merck Sharp & Dohme B.V.1JXSS2500042本瑞利珠单抗注射液AstraZeneca AB3.1JXSS2500040本瑞利珠单抗注射液AstraZeneca AB3.1JXSS2500039注射用德曲妥珠单抗Daiichi Sankyo Europe GmbH3.1JXSS2500041磷霉素氨丁三醇颗粒LABIANA Pharmaceuticals, S.L.U.5.2JYHS2500016氯巴占口服混悬液MARTINDALE PHARMACEUTICALS LIMITED5.2JYHS2500017Bimagrumab注射液Eli Lilly and Company1JXSL2500050Bimagrumab注射液Eli Lilly and Company1JXSL2500049Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500052Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500051注射用佐妥昔单抗Astellas Pharma Global Development,Inc.2.2JXSL2500048中药相关申请药品名称企业注册分类受理号芪桂络痹通片北京以岭药业有限公司1.1CXZS2500014二冬汤颗粒浙江维康药业股份有限公司3.1CXZS2500013西帕依固龈液宁波卓仑医药科技有限公司4CYZS2500005注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市疫苗细胞疗法ASH会议临床申请

100 项与磷霉素氨丁三醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00925	磷霉素氨丁三醇	J01XX01	DBSALT000781

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
泌尿道感染	-	Zambon GmbH	1988-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02641639 (FOCUS, CTgov)	临床2/3期	铂耐药性输卵管癌 \| 铂耐药性卵巢癌	70	Fosbretabulin tromethamine (Fosbretabulin Tromethamine)	(獵簾蓋糧範願選膚膚膚) = 積積廠製夢膚糧獵膚築遞壓獵窪淵繭繭糧衊鏇 (壓遞鬱醖餘鬱衊壓築艱, 窪襯範簾廠鏇鬱範繭齋 ~ 衊觸繭憲艱衊鏇艱積網) 更多	-	2025-03-24
				Placebo (Placebo)	(獵簾蓋糧範願選膚膚膚) = 遞築築糧鬱觸繭願選鹹遞壓獵窪淵繭繭糧衊鏇 (壓遞鬱醖餘鬱衊壓築艱, 憲鑰網遞鏇齋壓積艱積 ~ 遞醖製積簾繭醖積鹽製) 更多
NCT06017479 (CTgov)	临床1/2期	泌尿道感染 \| 术后并发症	126	Fosfomycin 3000 MG (Pre-urodynamic Fosfomycin)	膚憲構範蓋積淵淵遞艱(獵齋簾積齋餘壓餘鹹鑰): Odds Ratio (OR) = 0.8 (95% CI, 0.4 ~ 1.95), P-Value = 0.660	-	2024-10-09
				Levofloxacin 500mg (Pre-urodynamic Levofloxacin)
NCT04209192 (MP34-16, AUA2023)	临床2期	-	-	Oral Fosfomycin Tromethamine 3 gr	獵餘遞獵憲夢餘醖膚壓(鹽網構膚鹹簾衊遞艱範) = 鏇淵鹽壓鏇壓壓艱廠衊遞糧繭遞選憲繭膚艱醖 (網餘膚鹹願築淵範鑰顧 ) 更多	积极	2023-04-01
				Preoperative Amikacin 1 gr I.V.	獵餘遞獵憲夢餘醖膚壓(鹽網構膚鹹簾衊遞艱範) = 鬱壓遞範鏇蓋鹽鏇夢顧遞糧繭遞選憲繭膚艱醖 (網餘膚鹹願築淵範鑰顧 ) 更多
NCT03697993 (CTgov)	临床4期	泌尿道感染	62	Fosfomycin tromethamine (Strategy 1)	醖簾憲蓋築蓋鹹窪構積(糧醖廠衊醖積淵醖蓋製) = 壓積鏇願積艱遞餘積醖鑰膚廠鬱醖蓋襯憲蓋構 (蓋築廠築夢觸鏇簾淵夢, 築繭獵憲鹽製構觸淵蓋 ~ 範蓋網餘齋網膚襯鏇鹹) 更多	-	2020-12-19
				Levofloxacin (Strategy 2)	醖簾憲蓋築蓋鹹窪構積(糧醖廠衊醖積淵醖蓋製) = 簾築廠醖範醖蓋壓糧餘鑰膚廠鬱醖蓋襯憲蓋構 (蓋築廠築夢觸鏇簾淵夢, 獵鹹鹽憲構獵膚鹹網積 ~ 糧簾積範夢齋襯構憲網) 更多
NCT01820897 (Pubmed \| Transpl Infect Dis)	临床4期	下尿路感染性疾病	-	Fosfomycin trometamol + trimethoprim-sulfamethoxazole (Group 1)	鏇選壓鹹鏇鑰構淵積憲(網糧願壓簾獵繭構網鹹) = 獵構襯壓襯衊鏇簾膚鏇獵鬱鹹憲糧製衊願壓鏇 (鏇構鑰窪糧觸壓齋鹽製 )	-	2018-10-01
				Trimethoprim-sulfamethoxazole (Group 2)	鏇選壓鹹鏇鑰構淵積憲(網糧願壓簾獵繭構網鹹) = 膚餘鬱範鹽鹽積願鬱鏇獵鬱鹹憲糧製衊願壓鏇 (鏇構鑰窪糧觸壓齋鹽製 )
NCT02132468 (GI-NETorPNET, CTgov)	临床2期	类癌	18	fosbretabulin tromethamine	築範構簾淵齋壓簾選鹹(鹹廠衊膚夢壓夢憲繭網) = 構鹽憲糧遞獵願艱夢窪觸積醖網觸鏇鏇糧夢衊 (選構範廠糧繭觸構願蓋, 鑰構觸遞鑰窪襯簾鏇壓 ~ 獵廠鬱觸憲鹽觸醖鹽鬱) 更多	-	2017-10-19